The medical products and services firm has agreed to develop an Alzheimer's disease treatment with the Alzheimer's Disease Cooperative Study Group. Baxter International will conduct a late-stage trial of Gammagard Liquid, which contains a broad spectrum of antibodies known for targeting immunodeficiency conditions, to test its effectiveness in treating mild to moderate forms of the disease.

Related Summaries